Xcout IntelSign inSubscribe

SKINBIOTHERAPEUTICS PLC

SBTXBiotechNewcastle upon Tyne, United Kingdom

SkinBioTherapeutics Plc is a life sciences enterprise dedicated to enhancing human health through the exploration and development of technologies that harness the power of the human microbiome. The company has developed two primary technological platforms: SkinBiotix: This innovative solution is designed to strengthen the skin's natural barrier, offer protection against infections, and promote the repair of damaged skin. AxisBiotix: Focusing on the intricate link between gut health and skin conditions, this technology aims to mitigate the symptoms experienced by individuals with psoriasis. SkinBioTherapeutics serves a wide range of industries, including cosmetic and pharmaceutical skincare, nutritional supplements, and infection control. The company maintains active collaborations with key partners: Croda Plc; the University of Manchester, for the creation of microbiome formulations that bolster the immune system; and Winclove Probiotics B.V., with whom it's developing a unique probiotic blend derived from specific bacterial species known to influence psoriasis pathways. Originally founded in 2015 as Skinbiotix Ltd, the company adopted its current name, SkinBioTherapeutics plc, in December 2016. Its operations are headquartered in Newcastle upon Tyne, United Kingdom.

Subscribe to see SKINBIOTHERAPEUTICS PLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

SKINBIOTHERAPEUTICS PLC at a glance

SKINBIOTHERAPEUTICS PLC is a biotech company headquartered in Newcastle upon Tyne, United Kingdom, founded in 2015. It is publicly listed (SBTX) with a market capitalisation of $34.7M. Xcout tracks 17 named people at SKINBIOTHERAPEUTICS PLC, including Jeffrey C. Pepe (Interim Chief Executive Officer, Gen. Counsel & Corporation Sec.).

As of 16 November 2026. Source: Xcout Intel.

Industry
Biotech
Headquarters
Newcastle upon Tyne, United Kingdom
Market cap
$34.7M
Employees
41
Ticker
SBTX
Founded
2015

SKINBIOTHERAPEUTICS PLC leadership

  • Jeffrey C. PepeInterim Chief Executive Officer, Gen. Counsel & Corporation Sec.
  • Russ HawkinsonSenior Vice President of Fin., Interim Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
  • Peter A. Thompson FACPCo-Founder & Chairman of Directors
  • Sue HamkeSenior Vice President of Clinical Operations
  • Miguel ArcinasVice President of Corporation Devel. & Investor Relations
  • Dario GobunquinSenior Director of Accounting & Controller

11 more named people on record for SKINBIOTHERAPEUTICS PLC, with roles, board committees and tenure — see the full roster →

SKINBIOTHERAPEUTICS PLC competitors

A few of SKINBIOTHERAPEUTICS PLC's closest competitors — see the full list of competitors and alternatives →

OPTIBIOTIX HEALTH PLCBiotechYork, United Kingdom
74% match

OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, and tailored blends intended for integration into food products, nutritional supplements, and active ingredients. Their groundbreaking work aims to positively influence human physiology and yield substantial health benefits. Among its diverse product portfolio are Slimbiome, a natural ingredient for healthy and satiety-driven weight management, and SlimBiome Medical, a supplemental aid for weight control. Other offerings include CholBiome, a dietary supplement for maintaining healthy cholesterol; Lactobacillus plantarum LPLDL, a probiotic supporting cardiovascular health and overall well-being; LPGOS, a galactooligosaccharide utilized in food applications to mitigate cardiovascular risk factors and enhance general health; WellBiome, a functional fiber and mineral blend designed to bolster gut microbiome diversity and promote wellness; and Sweetbiotix, a sweetener for use in various foods and beverages. Ultimately, OptiBiotix's innovations are designed to prevent and manage prevalent chronic lifestyle diseases, including obesity, high cholesterol, and diabetes. The company was founded in 2012.

Valuation—
Employees—
OPTIBIOTIX HEALTH PLC competitors & alternatives →
Fortress Biotech, Inc.FBIO · BiotechBay Harbor Islands, FL, United States
67% matchPublic

Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.

Market cap$67M
Employees101
Fortress Biotech, Inc. competitors & alternatives →
Theriva Biologics, Inc.TOVX · BiotechRockville, MD, United States
66% matchPublic

Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.

Market cap$6.6M
Employees20
Theriva Biologics, Inc. competitors & alternatives →

Get SKINBIOTHERAPEUTICS PLC's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Something wrong or missing about SKINBIOTHERAPEUTICS PLC? Suggest a correction · Work at SKINBIOTHERAPEUTICS PLC? Claim this profile

Is this your company? Add the Xcout Intel badge to your website

Free, for any company on Xcout Intel. It links visitors to this profile.

SKINBIOTHERAPEUTICS PLC on Xcout Intel

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

SKINBIOTHERAPEUTICS PLC — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on SKINBIOTHERAPEUTICS PLC in Xcout Intel

  • 17 named people with titles, LinkedIn and board committees
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →